A client taking oral amiodarone reports a new dry cough and progressively worsening shortness of breath. Which action should the nurse take?

A new cough with progressive dyspnea can indicate amiodarone pulmonary toxicity, including pneumonitis. The symptoms require prompt clinical evaluation before further dosing rather than reassurance or symptom masking.

Quick answer
Report the cough and worsening dyspnea promptly and have the client evaluated before the next dose. This pattern can signal serious amiodarone pulmonary toxicity.

Why this is correct
Amiodarone can injure lung tissue and may cause pneumonitis or fibrosis. Early recognition matters because continued exposure while symptoms progress can worsen respiratory injury, and the treatment plan may need to change.

Easy analogy or mental picture
The symptoms are like smoke from wiring behind a wall: covering the smell does not address the hidden hazard. The analogy highlights early investigation, but only clinical assessment and testing can distinguish medication toxicity from infection or heart failure.

Memory hook
Amiodarone plus new cough and progressive dyspnea means think lung toxicity and report before redosing.

NCLEX decision rule
When a client taking amiodarone develops new respiratory symptoms, prioritize prompt evaluation for pulmonary toxicity. Do not label the symptoms expected, mask them with a cough product, or prescribe exercise before the cause is assessed.

Why the other choices are wrong
Pulmonary symptoms are not routine effects to dismiss. A cough medicine can delay recognition, and increasing exertion may stress a client whose gas exchange is worsening.